Coherus Oncology opens $50 million ATM channel through Leerink Partners
A $50.0 million at-the-market equity facility is in focus for Coherus Oncology (CHRS) after the Redwood City, California oncology company signed a sales agreement with Leerink Partners LLC on August 28, 2026, and filed a prospectus supplement the same day to activate it. The arrangement draws on a Form S-3 shelf registration, File No. 333-291520, that the SEC declared effective December 8, 2025. What to watch now is how quickly the company begins disclosing actual share sales in subsequent filings.
Key takeaways
- Coherus Oncology (CHRS) signed a sales agreement with Leerink Partners LLC on August 28, 2026, opening a $50.0 million at-the-market equity facility.
- The company filed a prospectus supplement the same day to activate the facility, drawing on a Form S-3 shelf registration (File No. 333-291520) that the SEC declared effective December 8, 2025.
- Leerink Partners earns a commission of up to 3.0% of gross proceeds and will sell CHRS common stock on Coherus's instructions, with no obligation for the company to sell any shares.
- Net proceeds are designated for general corporate purposes, including working capital, and either party may terminate the agreement with ten days' notice.
- The $50.0 million is a ceiling on aggregate offering price rather than a committed draw, and Coherus made no representations about when or whether it will use the facility.
A $50.0 million at-the-market equity facility is in focus for Coherus Oncology (CHRS) after the Redwood City, California oncology company signed a sales agreement with Leerink Partners LLC on August 28, 2026, and filed a prospectus supplement the same day to activate it. The arrangement draws on a Form S-3 shelf registration, File No. 333-291520, that the SEC declared effective December 8, 2025. What to watch now is how quickly the company begins disclosing actual share sales in subsequent filings.
Terms and mechanics
Under the agreement, Leerink Partners will sell shares of CHRS common stock, par value $0.0001 per share, on instructions from Coherus specifying any price, time, or size limits. Any sale method permitted under Rule 415(a)(4) of the Securities Act of 1933 qualifies. Leerink will use commercially reasonable efforts consistent with its normal trading and sales practices, per the filing. The agent earns a commission of up to 3.0% of gross proceeds on each sale, with Coherus providing customary indemnification and contribution rights in return.
The company carries no obligation to sell any shares under the agreement. That optionality is the core design of the ATM format: management can pace drawdowns without committing to a fixed schedule. Either party may terminate with ten days' notice, which keeps the arrangement lighter than a fixed underwriting commitment.
Net proceeds, after the agent's commission, are designated for general corporate purposes, with working capital specifically named in the filing. Chief Executive Officer Dennis M. Lanfear signed the 8-K on behalf of the company. Legal opinion on the validity of the shares comes from Latham & Watkins LLP, filed as Exhibit 5.1. The full text of the sales agreement is Exhibit 1.1.
What to watch
Coherus is incorporated in Delaware and lists on the Nasdaq Global Market. The S-3 shelf has been effective since December 8, 2025, meaning the filing infrastructure predated this specific agreement by several months. The August 28 prospectus supplement is the trigger that opens the Leerink channel for actual transactions.
The $50.0 million is a ceiling on aggregate offering price, not a committed draw. What moves the setup from here is the cadence of actual share sales disclosed in subsequent company filings, which will show how much of the facility Coherus is using and at what pace Leerink is placing shares. The filing explicitly states this 8-K does not constitute an offer to sell, and Coherus made no representations about when or whether it intends to draw on the facility.
Related reading
Filed by the newsroom of MarketPR on August 30, 2026. Source: sec.gov. Indicative figures are not investment advice.